Organon &

Organon & Intangible Assets

The Intangible Assets of Organon & (OGN) as of Oct 27, 2026 is 1.41 B USD. In the previous year, Intangible Assets was 533.00 M USD — a change of 165.29% (higher).

Intangible Assets

1.41 BUSD

YoY

165.29%

Last updated:

Intangible Assets of Organon & is 2024 1.41 B USD. Intangible Assets of Organon & was 2023 533.00 M USD. It decreases by 165.29% higher compared to the previous year.

The Organon & Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
812.00 M USD
Jan 1, 2019
569.00 M USD
Jan 1, 2020
503.00 M USD
Jan 1, 2021
651.00 M USD
Jan 1, 2022
649.00 M USD
Jan 1, 2023
533.00 M USD
Jan 1, 2024
1.41 B USD
The Organon & Intangible Assets history
YEARIntangible AssetsYoY
1.41 BUSD+165.29%
533.00 MUSD-17.87%
649.00 MUSD-0.31%
651.00 MUSD+29.42%
503.00 MUSD-11.60%
569.00 MUSD-29.93%
812.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

Intangible Assets of Organon & is 1.41 B USD in 2024.

Intangible Assets of Organon & changed from 533.00 M USD to 1.41 B USD, representing a 165.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Organon & since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Organon & historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Organon &

All Key Metrics — Organon &